Infliximab injectable solution is available as brand-name drugs. It’s not available in a generic version. Brand names: Remicade, Inflectra, Renflexis. Infliximab comes in an injectable solution for ...

A new post-hoc analysis from the LIBERTY studies, presented at ECCO 2026, demonstrated that initiating subcutaneous (SC) infliximab (Remsima™ SC) after a treatment interruption following intravenous ...

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for ...

Infliximab is a medication used to reduce the symptoms and signs of several chronic inflammatory disorders. It is approved for the treatment of Crohn’s disease, rheumatoid arthritis, psoriasis, ...

A Pediatric Blood and Marrow Transplant Consortium (PBMTC) survey was undertaken in early 2002 to capture information about current clinical practice using infliximab in children with GVHD to plan a ...

Infliximab is a monoclonal antibody that is administered intravenously to treat patients with chronic inflammatory diseases including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, plaque ...

Malvern, PA - The US Food and Drug Administration (FDA) has approved infliximab (Remicade, Centocor Inc) for treatment of ankylosing spondylitis (AS). Cautionary information included in the drug's ...

Learn everything you need to know about Infliximab-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Crohn’s Disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract with relapsing and remitting episodes. It is a disease that progresses over time, leading to complications such as ...

Infliximab dose de-escalation based on trough level proactive targeting represents an interesting therapeutic option for patients in clinical remission to reduce the risks of adverse events and ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of infliximab, having considered evidence on the nature of acute exacerbations of severely active ulcerative ...

The Appraisal Committee considered evidence submitted by the manufacturer of infliximab and a review of this submission by the Evidence Review Group (ERG). The manufacturer developed a systematic ...